Inhibrx Biosciences INBX 深 沪
已收盘 10-09 16:00:00 美东时间
95.01
+2.250
+2.43%
华盛通- 最 高95.81
- 今 开92.70
- 成交量 8.68万股
- 最 低 92.70
- 昨 收 92.76
- 总市值 139.83万
- 52周最高 155.29
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 28.16
- 委 比 0.00%
- 总股本 1.47万
- 历史最高 155.29
- 量 比 0.43
- 振 幅 3.35%
- 历史最低 7.67
- 每 手 1
- 风险率 20.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inhibrx Biosciences Updates Investor Presentation and Pipeline Outlook
Inhibrx Biosciences Inc ( ($INBX) ) has issued an update. On September 28, 2026...
09-29 05:27
Inhibrx, Eikon rise after insider buying
Shares of Inhibrx Biosciences (INBX) and Eikon Therapeutics (EIKN) traded higher on Wednesday as the cancer drug developers benefited from a series of insider purchases. Inhibrx (INBX) shares added mo...
09-10 00:21
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
Inhibrx Biosciences Inc ( ($INBX) ) has provided an announcement. On September ...
09-09 04:39
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Inhibrx Biosciences (INBX) traded higher in the premarket on Tuesday after announcing that INBRX-106, its experimental therapy for head and neck cancer, outperformed pembrolizumab, Merck’s (MRK) block...
09-08 21:27
Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candi...
09-05 04:02
美股周涨跌榜 | 绩优股周内集体飙升！爱芬奇劲升36%，Okta升23%，赛富时升逾22%
绩优股周内集体飙升！爱芬奇劲升36%，Okta升23%，赛富时升逾22%；RZLV升逾20%，与谷歌达成数据库技术合作>>
08-29 10:29
美股牛股 | Capricor飙近22%，获大行上调目标价至54美元；机器人股RR、稀土概念股Critical Metals双双升逾21%
Capricor隔夜飙升21.9%，获大行上调目标价至54美元；Richtech Robotics升21.6%，宣布1200万美元股票回购计划；稀土概念股Critical Metals劲升21.4%>>
08-26 19:31
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
08-24 18:21
Inhibrx Biosciences Expands Credit Facility to $500 Million
Inhibrx Biosciences Inc ( ($INBX) ) just unveiled an announcement. On July 15, ...
07-17 17:17
